Seizure control: How to use the new antiepileptic drugs in older patients

Geriatrics

Volumn 51, Issue 9, 1996, Pages 42-45

  Haider, Aamir ^a   Tuchek, John M ^a   Haider, Shariq ^b  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; GABAPENTIN; LAMOTRIGINE; LIVER ENZYME; PHENOBARBITAL; PHENYTOIN; VALPROIC ACID; VIGABATRIN;

CENTRAL NERVOUS SYSTEM DEPRESSION; CLINICAL TRIAL; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG PROTEIN BINDING; FOCAL EPILEPSY; GASTROINTESTINAL TOXICITY; HUMAN; REVIEW; SIDE EFFECT; SOMNOLENCE; VERTIGO;

ACETIC ACIDS; AGE FACTORS; AGED; AMINES; ANTICONVULSANTS; CYCLOHEXANECARBOXYLIC ACIDS; DRUG INTERACTIONS; DRUG MONITORING; GAMMA-AMINOBUTYRIC ACID; HUMANS; PATIENT SELECTION; SEIZURES; TRIAZINES; VIGABATRIN;

EID: 0030320266     PISSN: 0016867X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Hauser WA, Kurland LT. The epidemiology of epilepsy in Rochester, Minnesota, 1935 through 1967. Epilepsia 1975; 16:1.
2. Connelly JF. Vigabatrin. Ann Pharmacother 1993;27:197-204.
3. Messenheimer JA. New antiepileptic drugs. Resident & Staff Physician 1994; 40(6):31-5.
4. Chadwick D. Gabapentin. Lancet 1994; 343:89-91.
5. Goa KL, Ross SR, Chrisp P. Lamotrigine. A review of its pharmacological properties and clinical efficacy in epilepsy. Drugs 1993; 46(1):152-76.
6. Bruni J, Saunders M, Anhut H, Sauermann W. Efficacy and safety of gabapentin (Neurontin): A multicenter, placebo controlled, double blind study. Abstract. Neurology 1991; 41(suppl. 1):330.
7. UK Gabapentin Study Group. Gabapentin in partial epilepsy. Lancet 1990; 335:1114-7.
8. US Gabapentin Study Group No. 5. Gabapentin as add-on therapy in refractory partial epilepsy: A double blind, placebo controlled, parallel-group study. Neurology 1993; 43:2292-8.
9. Binnie CD, Debets RMC, Engelsman M, et al. Double blind crossover tried of lamotrigine (Lamictal) as add-on therapy in inractable epilepsy. Epilepsy Res 1989; 4:222-9.
10. Loiseau P, Yuen AWC, Duche B, Menager T, Arne-Bes MC. A randomized double blind placebo controlled crossover add-on trial of lamotrigine in patients with treatment-resistant partial seizures. Epilepsy Res 1990; 7:136-45.
11. Jawad S, Richens A, Goodwin G, Yuen WC. Controlled trial of lamotrigine (Lamictal) for refractory partial seizures. Epilepsia 1989; 30:356-63.
12. Gram L, Klosterskov P, Dam M. Gamma-vinyl GABA: A double blind placebo controlled trial in partial epilepsy. Ann Neurol 1985; 17:262-6.
13. Loiseau P, Hardenberg JP, Pestre M, Guyot M, Schechter PJ, Tell GP. Double blind, placebo-controlled study of vigabatrin (gammavinyl GABA) in drug resistant epilepsy. Epilepsia 1986; 27:115-20.
14. Ring HA, Helper AJ, Farr IN, Reynolds EH. Vigabatrin: Rational treatment for chronic epilepsy. J Neurol Neurosurg Psychiatry 1990; 53:1051-5.
15. Schechter PJ. Clinical pharmacology of vigabatrin. Br J Clin Pharmacol 1989; 27(suppl. 1):S19-22.
16. Jawad S, Yuen WC, Peck AW, Hamilton MJ, Oxzley JR. Lamotrigine: Single dose pharmacokinetics and initial 1 week experience in refractory epilepsy. Epilepsy Res 1987; 1(3):194-201.